Pei‐Sheng Wu

Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study

Le Li, Pei‐Sheng Wu, Xiumei Liang et al. · Journal of Gastroenterology · 2023 · 33 citations

Life Sciences, Immunology, Oncology +17

Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages

Da-Long Yang, Lin Ye, Fan-Jian Zeng et al. · Hepatology · 2025 · 24 citations

Medicine, Oncology, Immunotherapy +16

Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma

Dongli Sun, Shan‐Ding Huang, Pei‐Sheng Wu et al. · Chirality · 2009 · 15 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial

Li-Xin Pan, Yiyang Wang, Zhonghai Li et al. · Trials · 2024 · 12 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy

Rong‐Rui Huo, Li-Xin Pan, Pei‐Sheng Wu et al. · BJS Open · 2024 · 11 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +16